The agreement is expected to accelerate Peptris’ AI-powered drug discovery efforts and expand its footprint in global biotech markets

Peptris Technologies, an AI-powered drug discovery company, has entered into a licensing agreement with Revio Therapeutics, a speciality pharma start-up focussed on repurposing and optimising approved medicines. Under the agreement, Peptris is licensing its preclinical-stage asset, PEPR124 (RT001) for an undisclosed amount to Revio Therapeutics for further development in Duchenne Muscular Dystrophy (DMD).  The agreement is expected to accelerate Peptris’ AI-powered drug discovery efforts and expand its footprint in global biotech markets.

Under the terms of the agreement, Revio Therapeutics will hold commercialisation rights to PEPR124 (RT001) in all markets except in BRICS countries, which will be retained by Peptris.